Re: Cai et al.: Similar risk of kidney failure among patients with blinding diseases who receive ranibizumab, aflibercept, and bevacizumab: an observational health data sciences and informatics network study (Ophthalmol Retina. 2024;8:733–743)

Wan Ju Annabelle Lee

doi:10.1016/j.oret.2024.12.002

Re: Cai et al.: Similar risk of kidney failure among patients with blinding diseases who receive ranibizumab, aflibercept, and bevacizumab: an observational health data sciences and informatics network study (Ophthalmol Retina. 2024;8:733–743)

Department of Ophthalmology(NCKUH)

Research output: Contribution to journal › Letter › peer-review

Original language	English
Pages (from-to)	e17
Journal	Ophthalmology Retina
Volume	9
Issue number	3
DOIs	https://doi.org/10.1016/j.oret.2024.12.002
Publication status	Published - 2025 Mar

All Science Journal Classification (ASJC) codes

Ophthalmology

Access to Document

10.1016/j.oret.2024.12.002

Cite this

@article{23c4a920ee924e4d9e25cd86c8f94d81,

title = "Re: Cai et al.: Similar risk of kidney failure among patients with blinding diseases who receive ranibizumab, aflibercept, and bevacizumab: an observational health data sciences and informatics network study (Ophthalmol Retina. 2024;8:733–743)",

author = "{Annabelle Lee}, {Wan Ju}",

year = "2025",

month = mar,

doi = "10.1016/j.oret.2024.12.002",

language = "English",

volume = "9",

pages = "e17",

journal = "Ophthalmology Retina",

issn = "2468-7219",

publisher = "Elsevier Inc.",

number = "3",

}

Re: Cai et al.: Similar risk of kidney failure among patients with blinding diseases who receive ranibizumab, aflibercept, and bevacizumab: an observational health data sciences and informatics network study (Ophthalmol Retina. 2024;8:733–743). / Annabelle Lee, Wan Ju.
In: Ophthalmology Retina, Vol. 9, No. 3, 03.2025, p. e17.

Research output: Contribution to journal › Letter › peer-review

TY - JOUR

T1 - Re

T2 - Cai et al.: Similar risk of kidney failure among patients with blinding diseases who receive ranibizumab, aflibercept, and bevacizumab: an observational health data sciences and informatics network study (Ophthalmol Retina. 2024;8:733–743)

AU - Annabelle Lee, Wan Ju

PY - 2025/3

Y1 - 2025/3

UR - http://www.scopus.com/inward/record.url?scp=85217104070&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85217104070&partnerID=8YFLogxK

U2 - 10.1016/j.oret.2024.12.002

DO - 10.1016/j.oret.2024.12.002

M3 - Letter

AN - SCOPUS:85217104070

SN - 2468-7219

VL - 9

SP - e17

JO - Ophthalmology Retina

JF - Ophthalmology Retina

IS - 3

ER -

Re: Cai et al.: Similar risk of kidney failure among patients with blinding diseases who receive ranibizumab, aflibercept, and bevacizumab: an observational health data sciences and informatics network study (Ophthalmol Retina. 2024;8:733–743)

All Science Journal Classification (ASJC) codes

Access to Document

Other files and links

Cite this